Allergan launches Ubrelvy

Sandra Levy
Senior Editor
Sandra Levy profile picture

Adults with acute migraine with or without aura have a new oral treatment option: Ubrelvy (ubrogepant).

Following approval by the Food and Drug Administration in December, Allergan is making the product availalble.

Ubrelvy is the first and only oral calcitonin gene-related peptide receptor antagonist FDA approved for the treatment of migraine attacks once they start.

Migraine is a neurological disease characterized by intermittent migraine attacks with symptoms that are often incapacitating.